Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

For Alice Shaw, Dana-Farber Cancer Institute’s Chief of Strategic Partnerships, the best is however yet to come. “There is so much excitement around these RAS therapies,” says Shaw ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...

GLP-1RAs were not associated with an increased risk for thyroid cancer relative to DPP-4 inhibitor use among an international cohort.

A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have uncovered a powerful combination therapy leveraging sotorasib-an FDA-approved ...

RVMD), a biotechnology company with a market capitalization of $7.3 billion focused on developing novel therapies for cancer, has been making significant strides in its RAS inhibitor pipeline.

A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have ...

Fatty pancreas disease, characterized by intra-pancreatic fat deposition, is more prevalent than diabetes, pancreatitis, and ...